Cara Therapeutics (CARA) Tops Q4 EPS by 6c

Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity